SCHEMBL10065846

SCHEMBL10065846

CN[C@H](CC(=O)O)CC(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.47
CACNB3 P54284 1/20 0.47
CACNA1C Q13936 1/20 0.47
PGR P06401 1/20 0.47
ADRA1A P35348 1/20 0.47
HTR2B P41595 1/20 0.47
CACNA2D2 Q9NY47 1/20 0.47
ANPEP P15144 1/20 0.45
ENPEP Q07075 1/20 0.45
PLA2G10 O15496 3/20 0.43
MME P08473 2/20 0.41
RNPEP Q9H4A4 1/20 0.38
SLC7A5 Q01650 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KISS1R Q969F8 1/20 0.37
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
CPA1 P15085 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13851759 1.00 CACNA2D1 (0.47) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL24965252 1.00 CACNA2D1 (0.47) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL585119 0.83 ANPEP (0.48) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL17992778 0.82 ALDH1A1 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL25641484 0.82 ALDH1A1 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL20342119 0.82 ALDH1A1 (0.50) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL15592753 0.80 CACNA2D1 (0.45) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL27773495 0.80 PLA2G10 (0.49) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL27752676 0.80 PLA2G10 (0.49) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL13851589 0.80 CACNA2D1 (0.45) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US disclosed
US-20120071329-A1 METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES GLAXOSMITHKLINE LLC (US) 2012-03-22 US disclosed
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES GLAXOSMITHKLINE (US) 2011-10-13 US disclosed
US-7989395-B2 Methods for identifying compounds of interest using encoded libraries GLAXOSMITHKLINE LLC (US) 2011-08-02 US disclosed
US-7935658-B2 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS, INC. (US) 2011-05-03 US disclosed
US-20090062147-A1 Methods for synthesis of encoded libraries PRAECIS PHARMACEUTICALS INCORPORATED (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251089-A1 METHODS FOR SYNTHESIS OF ENCODED LIBRARIES RNGTT, DTYMK, DUT CACNA2D1 4673/4885CACNB3 3674/4885CACNA1C 4770/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 CACNA2D1 3895/4885CACNB3 2520/4885CACNA1C 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.